Type 2 diabetes mellitus (type 2 DM) is an important disease with increasing prevalence
worldwide. More than 60% of diabetes patients die of CVD. Diabetes is associated with 2-to 4-
fold increase in the risk of coronary artery disease (CAD). Diabetes patients with stable
ischemic heart disease may have more prevalent of asymptomatic ischemia or silent ischemia
due to autonomic neuropathy. Therefore, detection of total myocardial ischemia including both
symptomatic and silent ischemia using ambulatory electrocardiogram monitoring may provide
better accuracy in ischemic burden and prognosis in diabetes patients. DDP-4 inhibitors have
favorable effects on atherosclerotic risk factors beyond glycemic control. Furthermore, DPP-4
inhibitors may have favorable effects on ischemic preconditioning in patients with CAD. For
this study we aim to compare the effects of between vildagliptin and Dapagliflozin on
ischemic burden defined by total ischemic time, markers of autonomic function, biomarkers of
myocardial injury and biomarkers of inflammation.
Phase:
Phase 4
Details
Lead Sponsor:
Chiang Mai University
Treatments:
Dapagliflozin Dipeptidyl-Peptidase IV Inhibitors Vildagliptin